Rare Disease & Orphan Drugs
Gene therapy was their last hope for a second birthday.
He’s now celebrating his 8th.
That is what drives us. Experience, Rho.
When it comes to treating rare diseases, Rho understands that advancements don’t come easy and the rarity of the diseases alone can inhibit the success of clinical trials.
Unfortunately, less than 10% of rare diseases have a specific treatment, most have no cure at all, and many manifest at a young age. Combining the COVID-19 pandemic with a limited population and lack of disease education and funding, their rare disease isn’t the only thing causing these families to feel alone.
Starting with unique regulatory pathways and continuing through drug development and marketing applications, the differences inherent to rare and orphan disease clinical trials are ever-present and require a knowledgeable, empathetic and flexible CRO with the expertise to design and execute your orphan drug development plan, including the ability to incorporate decentralized clinical trial solutions.
With over 30,000 rare disease participants treated in more than 150 studies and 2,400 sites, along with our own personal experiences supporting friends and family struggling with rare diseases, Rho not only feels their pain – we’re determined to help find the cure.
Our relationships are leading the charge. To better support and aid the development of your product, we’ll lean hard on our strong relationships with advocacy organizations and clinical sites to simplify recruitment and increase retention while meeting regulatory requirements – ultimately providing more feasible and flexible rare disease clinical trials.
Our collaborative relationship with Rho has been instrumental in the implementation of a complex and rigorous first in human genetic medicine study, including strategic solutions for unique challenges faced in rare disease gene therapy trials. Rho has leveraged existing relationships with patient advocacy organizations and worked closely with a centralized biosafety review partner early in study startup to help identify and mitigate potential challenges.
Monica Gangal – Former VP of Clinical Operations at Anthera
Met or exceeded timelines for site activations, enrollment, data cleaning and lock for the past
Through the Cystic Fibrosis Foundation Therapeutics Development Network,
Gene and Cellular Therapy
With approximately 80% of all rare diseases having a genetic component, utilizing an orphan drug and rare disease CRO partner with expertise developing, conducting, and managing these trials is vital to the success of your program. And with over 20 studies in more than 1,000 participants, our understanding of these trials will help you plan for and prevent the inherent risks associated with gene and cellular therapy research.
Natural History Studies
Understanding and defining the disease course is critical when developing a rare disease therapy. Current FDA guidance documents even stress the importance of referencing Natural History Studies (NHS) to inform drug development. Having conducted over 30 NHSs, let our expertise assist your drug development program.
Kevin Barber, Ph.D.
Vice President, Regulatory Strategy & Submissions
Karen Kesler, Ph.D.
Associate Vice President, Federal Research Science
Joseph Watson, Ph.D.
Associate Director, Regulatory Strategy
Senior Project Manager
Caitlin Hirschman, R.N.
Principal Clinical Team Lead
Clinical Team Lead
Clinical Team Lead
Principal Clinical Data Manager
Rare Disease CRO Services
Clinical Project Management
Clinical Monitoring & Operations
Risk-Based Quality Management
Clinical Data Management
Randomization & Trial Supply Management